Board Meeting6 Nov 2026, 09:23 pm
Kilitch Drugs Board Approves Unaudited Financial Results
AI Summary
Kilitch Drugs India Ltd announced the outcome of its Board meeting held on November 6, 2026. The Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026. Additionally, the company approved the conversion of its outstanding debt in its Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), into equity and the subsequent divestment of its entire shareholding in KEB to HarmeeCare Pharmaceuticals for USD 14.00 million. This transaction is subject to regulatory approvals.
Key Highlights
- Board approved unaudited financial results for Q2 FY27 and H1 FY27.
- Results were standalone and consolidated.
- Approved conversion of debt in Ethiopian subsidiary to equity.
- Approved divestment of Ethiopian subsidiary for USD 14 million.
- Transaction is subject to regulatory approvals.
Price Impact
More from KILITCH